Abstract
Purchase PDF (162 K)
E-mail Article
Add to my Quick Links
Cited By in Scopus (0)
Purchase PDF (426 K)
doi:10.1016/j.bbrc.2005.11.179 
Copyright © 2005 Elsevier Inc. All rights reserved.
Improving effect of ethyl eicosapentanoate on statin-induced rhabdomyolysis in Eisai hyperbilirubinemic rats
Received 12 November 2005.
References and further reading may be available for this article. To view references and further reading you must purchase this article.
Abstract
The effect of ethyl eicosapentanoate (EPA-E) on statin-induced rhabdomyolysis was investigated by co-administration of EPA-E and pravastatin (PV), as a typical statin, to Eisai hyperbilirubinemic rats (EHBR). It was confirmed that the plasma PV concentration was not affected by simultaneous administration of EPA-E, and there was no cumulative increase of PV during prolonged co-administration of EPA-E and PV. Muscular degeneration was prominent (incidence 5/5; average grade 3.5 (range 2–4)) in EHBR treated with PV alone at 200 mg/kg/day for 14 days, but co-administration of EPA-E at doses of 100, 300, and 1000 mg/kg/day decreased the average grades to 1.4 (range 0.3–3.0), 0.5 (0.2–1.0), and 0.6 (0.0–1.7), respectively. Creatine phosphokinase (CPK) and myoglobin levels in plasma were well correlated with the grade of skeletal muscle degeneration. Thus, EPA-E appears to reduce the severity of statin-induced rhabdomyolysis.
Keywords: Statin; Ethyl eicosapentanoate; EPA-E; Rhabdomyolysis; Myopathy; Pravastatin; EHBR
p < 0.05, significantly different from the group D by Student’s t test or Welch’s test.